GHK-Cu injection vs topical has no head-to-head answer. Most human studies have used topical products, meaning creams, serums or gels applied to skin. No published trial has tested injected GHK-Cu on its own for skin, hair or wound healing. Getting past the skin barrier doesn't establish a better result.
GHK-Cu is a peptide, a short chain of protein building blocks, attached to copper. Scientists study its role in tissue repair; the guide to what GHK-Cu does explains that biology.
GHK-Cu injection vs topical: what has been tested?
The evidence is uneven, rather than a contest with a clear winner.
As of October 29, 2026, the day this article was written, an August 20 review by Mokhtar and colleagues in Aesthetic Surgery Journal puts the gap in perspective. It counted 20 eligible studies of cosmetic uses: 18 preclinical studies, meaning laboratory or animal work, and two randomized human trials, which assign treatment by chance. Its search ended in March 2026. That count concerns cosmetic uses, rather than every GHK-Cu experiment.
| Route or setting | What the evidence concerns | What it cannot establish |
|---|---|---|
| Skin-care products | Small human studies of particular formulas | Results from every copper-peptide serum |
| Wound gels | Human studies alongside organized wound care | Results on ordinary facial skin or from injections |
| Injections | One uncontrolled human scalp study of a mixture | Benefits or long-term safety of injected GHK-Cu alone |
Topical results are mixed. The review reported less wrinkle volume and depth than in control groups, while noting few well-designed trials and varied methods. In Miller and colleagues' 2006 Archives of Facial Plastic Surgery trial, 13 people completed follow-up after laser treatment. Satisfaction favored GHK-Cu skin care, but measured redness, wrinkles and overall skin quality did not differ between groups.
Medical wound care is another setting altogether. The GHK-Cu wound-healing study guide covers those trials. Their results don't turn a cosmetic serum into a wound treatment.
Does topical GHK-Cu actually absorb?
Copper can cross skin under laboratory conditions. That doesn't tell us how much of a particular serum reaches living tissue, or whether it changes someone's skin.
Hostynek and colleagues' 2010 Inflammation Research experiment applied a copper-peptide solution to human skin removed from the body. Researchers measured copper passing through different skin layers and copper left in the tissue. They weren't treating volunteers.
The measurement followed copper, without establishing how much remained attached to the original peptide. It also didn't measure wrinkle changes, hair growth or blood levels in a living person.
The journal's erratum identifies the commonly cited 2011 paper as a preliminary duplicate of the 2010 final version. These aren't two independent confirmations.
A cream's base, the ingredient's stability and the condition of the skin all matter. A percentage on a label describes what's in the container, not the amount delivered. The GHK-Cu dosage guide explains why a topical percentage cannot set an injection amount.
Do microneedles change the answer?
Microneedles are tiny points designed to cross the skin's protective surface. Better delivery is a separate question from better results.
As of October 29, 2026, the day this article was written, a September 9 study by Sadeqi and colleagues in Advanced Healthcare Materials adds delivery evidence. It tested STAR particles, small particles with needle-shaped tips, using pig skin kept in a laboratory. They increased copper-peptide delivery. The experiment didn't measure wrinkle improvement, healing or safety in patients.
As of October 29, 2026, the day this article was written, new human work is still asking different questions. A study registration first posted October 22, 2026 includes GHK-Cu in a topical peptide serum alongside other treatment components. It has no posted results and doesn't compare topical GHK-Cu with an injection.
What do we know about injected GHK-Cu?
The missing evidence concerns GHK-Cu on its own. A 2018 study by Kapoor and Shome in Journal of Cosmetic and Laser Therapy did inject a mixture containing copper tripeptide-1, another name for GHK-Cu, into scalps. It also contained several growth factors, proteins that influence cell activity, and had no comparison group. It cannot isolate the copper peptide's contribution.
As of October 29, 2026, the day this article was written, searches of PubMed, a medical research database, and the ClinicalTrials.gov registry of study plans identify no published trial establishing injected GHK-Cu alone for skin, hair or wound healing. There is no human trial comparing the two routes directly.
The hair evidence and GHK-Cu versus retinol comparison address those separate treatment questions. Neither supplies evidence that injections outperform a cream.
How do the safety questions differ?
Creams and serums can cause irritation or contact dermatitis, an itchy skin rash. Guidance from the Food and Drug Administration (FDA) explains that fragrances, preservatives and other ingredients can cause allergic reactions. A reaction to a copper-peptide serum therefore isn't automatically a reaction to GHK-Cu. A reliable GHK-Cu-specific irritation rate is missing.
Injections add questions about local pain, redness, swelling and the preparation's sterility, meaning freedom from germs. Those are possible injection problems, not measured GHK-Cu reaction percentages. FDA's safety page, marked current as of April 22, 2026, lists injectable GHK-Cu among withdrawn nominations. That entry, written for injectable routes only, notes limited human safety data and a possible risk of immune reactions related to peptide clumping and impurities. The side-effects guide separates those concerns.
Copper exposure matters too. Dietary limits concern copper from food and supplements; they aren't injection safety thresholds. Conditions that affect how the body handles copper, such as Wilson disease (an inherited condition in which copper builds up), and liver history belong in the review. The questions to ask before GHK-Cu cover that conversation.
What changes when GHK-Cu is in a blend?
KLOW combines GHK-Cu with three other peptides: BPC-157, TB-500 and KPV. Research on an individual ingredient doesn't establish what the complete blend adds, how its ingredients behave together or how unwanted effects change.
Is a serum the same as a compounded prescription?
Cosmetic serums and prescribed medicines answer different questions. FDA explains that intended use determines whether something is a cosmetic, a drug or both. A serum marketed to improve appearance may be a cosmetic; claims to treat disease or change body structure can make it a drug.
Compounded means prepared by a pharmacy for a prescription. GHK-Cu is not FDA-approved for any use, and the compounded formulation offered here is not FDA-approved. FDA does not review compounded medicines for safety, effectiveness or quality before marketing.
As of October 29, 2026, the day this article was written, FDA's nominations document, marked “Updated May 14, 2026”, lists non-injectable GHK-Cu under evaluation and records the injectable nomination's withdrawal. The GHK-Cu FDA review explains those separate entries.
As of October 29, 2026, the day this article was written, a Department of Health and Human Services (HHS) draft enforcement policy filed October 28 says HHS does not intend to take enforcement action against compounding with six listed peptides when all of the circumstances it lists are present; the draft is not binding. GHK-Cu is absent from Appendix A; the HHS policy explainer covers the details.
A licensed provider may still prescribe — that decision is between you and your doctor.
What a useful visit can settle
A clinician can connect the concern, the proposed preparation and the evidence that actually matches it. The discussion includes previous treatments, copper exposure, reactions and what follow-up could measure.
At Promise, a licensed provider reviews every request, and not everyone qualifies. If prescribed, medication is compounded and dispensed by a licensed U.S. compounding pharmacy.
